DarkHorse Podcast

Pharma’s New Game: The 279th Evolutionary Lens with Bret Weinstein and Heather Heying

49 snips
Jun 4, 2025
The hosts dive into the controversial FDA approval of Moderna's new mRNA vaccine, raising concerns about transparency and efficacy. They tackle the complexities of public discourse and the challenges of discerning truth amidst competing narratives. A captivating discussion on the gender identity controversy surrounding an Algerian boxer highlights the nuances of biological observation versus interpretation. Finally, they explore the role of religion in societal cohesion and reflect on the intersection of pathogens and cultural evolution.
Ask episode
AI Snips
Chapters
Books
Transcript
Episode notes
INSIGHT

Moderna's New Vaccine Dose Lowers Risk?

  • The new Moderna mRNA COVID-19 vaccine significantly reduces the active dose compared to the original shot.
  • Lower dosage might reduce harm but unclear if efficacy is maintained due to insufficient information.
INSIGHT

Pharma's Trial Control Risk

  • Pharma often controls its own trials through contractors with vested interests.
  • This structure allows for gaming trial results without clear blindness or accountability.
INSIGHT

Lack of Mucosal Immunity Is Intentional

  • COVID shots fail to induce mucosal immunity, the key barrier to respiratory virus infection.
  • Pharma benefits by letting disease spread to maintain market demand for vaccines.
Get the Snipd Podcast app to discover more snips from this episode
Get the app